$ONC mention timeline

BeiGene. Every tracked FinTwit mention of $ONC, newest first. 23 mentions since the first on Jun 30, 2025. See the price chart.

May 2026 · 2 mentions

May 31
Jacob Plieth — MSKCC's Sarc041 trial of Verzenio being discussed at #Asco26 plenary right now... actually a really interesting study, but more for $PFE $ONC CDK4 inhibitors than for $LLY, I recko…↗
May 6
Jacob Plieth — So $ONC BG-68501, BG-60366, BG-89894 & BGB-53038 discontinued?↗

Apr 29
Jacob Plieth — If you're wondering what $ONC got for its $20 m, here's the #AACR25 detail on Huahi's HH160, a symmetrical hexavalent trispecific anti PD-1 x CTLA-4 x VEGF-A MAb https://t.co/Y0jVj…↗
Apr 22
Jacob Plieth — @PersimmonTI $ONC told us it's paused the trial while it evaluates data. No idea what's prompted that, but a tox signal seems possible.↗
Apr 17
Jacob Plieth — ...and now $ONC EGFR degrader BG-60366 appears to have been discontinued - recruitment ended after enrolling just 33 of planned 93 patients.↗
Apr 9
Jacob Plieth — @STL_Biotech $ONC for instance: https://t.co/LFJCsl1MQj

Mar 16
Jacob Plieth — Since my 2024 look at CCR8 a lot has happened: $BMY $GILD $ABBV upsized; $ONC Bayer $ZLAB (& soon $AMGN?) discontinued. @BatirtzeAreitio investigates, via @ApexOnco -> https…↗

Feb 6
Jacob Plieth — If $ABBV BTK degrader ABBV-101 has been discontinued (Evercore ISI confirms to us that it has) that's good news for $ONC & $NRIX -> https://t.co/aF1sORkqDY↗

Jan 9
Jacob Plieth — Ascentage just disclosed that it's developing a BTK degrader: APG-3288 apparently just had its US IND cleared $ONC $NRIX↗
Jan 2
Jacob Plieth — That's confirmed now - #GI26 late-breaking abstract LBA285 $JAZZ $ONC $ZYME↗

Dec 22
Jacob Plieth — $AZN follows $LLY $PFE $AMGN $ONC & $ALPMF into pan-KRAS, but should it be looking more to pan-RAS approaches like $RVMD & $ERAS? Via @ApexOnco -> https://t.co/MioOWziu…↗
Dec 22
Jacob Plieth — @NotGenentech @bioinvestor24 Here's a list of just the clinical pan-RAS & pan-KRAS assets from Oncologypipeline $RVMD $LLY $ONC $RHHBY $PFE $ERAS $AZN $AMGN $ALPMF https://t.co…↗
Dec 9
Jacob Plieth — If you enjoyed #ASH25 you can catch up on all @ApexOnco coverage, including previews, here -> https://t.co/XIQrEeKMwY $TERN $JNJ $LLY $CGEM $ONC $NRIX $PFE $REGN $KURA↗
Dec 9
Jacob Plieth

Nov 27
Jacob Plieth — If you need some biotech reading over Thanksgiving check out @ApexOnco previews of #ASH25 --> https://t.co/cqsR1AVbPH Starts in just over a week! $ACLX $ONC $CRVS $TERN $KURA $S…↗
Nov 26
Jacob Plieth — Just accepted for FDA priorty review. "The treatment was well tolerated, and the risks were manageable", so that's all right then! $ONC↗

Sep 17
Jacob Plieth — First $AFMD, now $IPHA... what say $ONC & any others still involved in NK-cell engagers?↗

Jul 24
Jacob Plieth — Nanjing Leads IPO document reveals that $ONC terminated its Lag3 deal in May. Should start trading tomorrow. Via @ApexOnco -> https://t.co/njxW3Ih5vU↗
Jul 4
Jacob Plieth — Guess who's about to take a SC anti-PD-1 into phase 3? Via @ApexOnco -> https://t.co/TNXStCSSIo $ONC $BGNE $RHHBY $AZN $MRK $BMY $PFE↗

Jun 30
Jacob Plieth — $ONC $BGNE confirmed to us that it's working both on a Ras(on) inhibitor, and on developing ADCs that use this Ras(on) inhibitor as a "non-cytotoxic payload".↗
Jun 30
Jacob Plieth — You already have a small-molecule inhibitor, so do you also need a degrader? $ONC $BGNE thinks yes, for BTK, CDK2 & Kras. Via @ApexOnco -> https://t.co/LFJCsl1MQj $ARVN $GIL…↗